<DOC>
	<DOCNO>NCT02130362</DOCNO>
	<brief_summary>This registry study evaluate long-term safety effectiveness adalimumab pediatric patient moderately severely active CD treat recommended local product label .</brief_summary>
	<brief_title>A Non-Interventional Clinical Study Evaluate Long-Term Safety Effectiveness HUMIRA ( Adalimumab ) Pediatric Patients With Moderately Severely Active Crohn 's Disease ( CD )</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>For patient enrol HUMIRA treatment group ; A pediatric patient age 6 17 year inclusive time enrollment , diagnose moderately severely active CD prescribe Humira therapy accord routine clinical practice . For patient enrol immunosuppressant therapy treatment group ; A pediatric patient age 6 17 year inclusive time enrollment , diagnose moderately severely active CD prescribe azathioprine , 6mercaptopurine methotrexate . Parent guardian ; patient ( 18 year age old enrollment roll AbbViesponsored investigational Pediatric CD investigation trial ) voluntarily sign date Authorization Use/Disclosure Data ( AUDD ) /informed consent form ( ICF ) nature registry explain patient , patient 's parent legal guardian opportunity ask question . Patients enrol registry currently treat investigational agent receive investigational procedure . Patients enrol immunosuppressant therapy treatment group require ongoing treatment approve biologic agent include HUMIRA .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adalimumab</keyword>
	<keyword>Crohn 's</keyword>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Registry</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Inflammatory Bowel Diseases</keyword>
</DOC>